Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + chemotherapy as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2000034333Phase 4Recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Xuzhou Central Hospital. Primary endpoint: Objective response rate. Started Jul 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranibcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000034333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034333.